Saltar al contenido
Merck

NPFF Decreases Activity of Human Arcuate NPY Neurons: A Study in Embryonic-Stem-Cell-Derived Model.

International journal of molecular sciences (2022-03-26)
Lola Torz, Kristoffer Niss, Sofia Lundh, Jens C Rekling, Carlos Damian Quintana, Signe Emilie Dannulat Frazier, Aaron J Mercer, Anda Cornea, Charlotte Vinther Bertelsen, Marina Kjærgaard Gerstenberg, Ann Maria Kruse Hansen, Mette Guldbrandt, Jens Lykkesfeldt, Linu Mary John, J Carlos Villaescusa, Natalia Petersen
RESUMEN

Restoring the control of food intake is the key to obesity management and prevention. The arcuate nucleus (ARC) of the hypothalamus is extensively being studied as a potential anti-obesity target. Animal studies showed that neuropeptide FF (NPFF) reduces food intake by its action in neuropeptide Y (NPY) neurons of the hypothalamic ARC, but the detailed mode of action observed in human neurons is missing, due to the lack of a human-neuron-based model for pharmacology testing. Here, we validated and utilized a human-neural-stem-cell-based (hNSC) model of ARC to test the effects of NPFF on cellular pathways and neuronal activity. We found that in the human neurons, decreased cAMP levels by NPFF resulted in a reduced rate of cytoplasmic calcium oscillations, indicating an inhibition of ARC NPY neurons. This suggests the therapeutic potential of NPFFR2 in obesity. In addition, we demonstrate the use of human-stem-cell-derived neurons in pharmacological applications and the potential of this model to address functional aspects of human hypothalamic neurons.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Monoclonal Anti-MAP2 antibody produced in mouse, clone HM-2, ascites fluid
Sigma-Aldrich
Smoothened Agonist, SAG, InSolution, ≥95%, 10 mM aqueous solution